Comments

Verve Therapeutics

VERVNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$7.18
0.294.21%
At Close: -
$7.27
0.091.20%
After Hours: 6:02 PM EDT
15 minutes delayed
Verve Therapeutics (VERV) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$62.00
Lowest Price Target1
$13.00
Consensus Price Target1
$33.56

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Verve Therapeutics (NASDAQ:VERV) Stock, Analyst Ratings, Price Targets, Forecasts

Verve Therapeutics Inc has a consensus price target of $33.56 based on the ratings of 9 analysts. The high is $62 issued by BMO Capital on July 18, 2022. The low is $13 issued by Goldman Sachs on December 15, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Stifel, and RBC Capital on May 9, 2024, April 3, 2024, and February 28, 2024, respectively. With an average price target of $30 between HC Wainwright & Co., Stifel, and RBC Capital, there's an implied 312.86% upside for Verve Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
0
0
0
0
Apr
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Stifel
RBC Capital
Cantor Fitzgerald
Guggenheim

1calculated from analyst ratings

Analyst Ratings for Verve Therapeutics

Buy NowGet Alert
05/09/2024Buy Now106.43%HC Wainwright & Co.
Mitchell Kapoor
 → $15ReiteratesBuy → BuyGet Alert
04/03/2024Buy Now450.48%Stifel
Dae Gon Ha
$56 → $40MaintainsBuyGet Alert
02/28/2024Buy Now381.67%RBC Capital
Luca Issi
 → $35ReiteratesOutperform → OutperformGet Alert
09/13/2023Buy Now202.76%Cantor Fitzgerald
Rick Bienkowski
 → $22ReiteratesNeutral → NeutralGet Alert
08/29/2023Buy Now202.76%Cantor Fitzgerald
Rick Bienkowski
 → $22ReiteratesNeutral → NeutralGet Alert
08/15/2023Buy Now656.91%Guggenheim
Seamus Fernandez
$56 → $55MaintainsBuyGet Alert
08/11/2023Buy Now326.62%Credit Suisse
Richard Law
 → $31ReiteratesNeutral → NeutralGet Alert
06/16/2023Buy Now299.1%Canaccord Genuity
Whitney Ijem
 → $29ReiteratesBuy → BuyGet Alert
05/16/2023Buy Now381.67%RBC Capital
Luca Issi
 → $35ReiteratesOutperform → OutperformGet Alert
04/13/2023Buy Now299.1%Canaccord Genuity
Whitney Ijem
 → $29Initiates → BuyGet Alert
02/01/2023Buy Now189%Cantor Fitzgerald
Rick Bienkowski
 → $21Initiates → NeutralGet Alert
12/15/2022Buy Now78.91%Goldman Sachs
Andrea Tan
 → $13Initiates → SellGet Alert
11/08/2022Buy Now381.67%RBC Capital
Luca Issi
$42 → $35MaintainsOutperformGet Alert
10/06/2022Buy Now560.57%Credit Suisse
Richard Law
 → $48Initiates → NeutralGet Alert
08/25/2022Buy Now670.67%Stifel
Dae Gon Ha
$32 → $56UpgradeHold → BuyGet Alert
07/18/2022Buy Now753.24%BMO Capital
Kostas Biliouris
$48 → $62MaintainsOutperformGet Alert
06/17/2022Buy Now560.57%BMO Capital
Kostas Biliouris
 → $48Initiates → OutperformGet Alert
02/18/2022Buy Now478%RBC Capital
Luca Issi
 → $42Initiates → OutperformGet Alert
09/24/2021Buy Now698.19%Stifel
Dae Gon Ha
—Initiates → HoldGet Alert

FAQ

Q

What is the target price for Verve Therapeutics (VERV) stock?

A

The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by HC Wainwright & Co. on May 9, 2024. The analyst firm set a price target for $15.00 expecting VERV to rise to within 12 months (a possible 106.43% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verve Therapeutics (VERV)?

A

The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by HC Wainwright & Co., and Verve Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Verve Therapeutics (VERV)?

A

The last upgrade for Verve Therapeutics Inc happened on August 25, 2022 when Stifel raised their price target to $56. Stifel previously had a hold for Verve Therapeutics Inc.

Q

When was the last downgrade for Verve Therapeutics (VERV)?

A

There is no last downgrade for Verve Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.

Q

Is the Analyst Rating Verve Therapeutics (VERV) correct?

A

While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a reiterated with a price target of $0.00 to $15.00. The current price Verve Therapeutics (VERV) is trading at is $7.27, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch